

MONOCAST *Film Coated Tablets*

ZAFIRLUKAST

Composition:

Each tablet contains : Zafirlukast 20 mg.

Properties:

Zafirlukast is a selective and competitive receptor antagonist of Leukotriene D₄ and E₄ (LTD₄ and LTE₄) components of slow-reacting substance of anaphylaxis (SRSA). It reduces the risk of asthma exacerbations and the need for additional anti-asthma therapies. MONOCAST plays a role in the pathogenesis of asthma. It suppresses both early and late broncho-constrictor responses to inhaled antigens or irritants.

Zafirlukast is rapidly absorbed after oral administration (Peak plasma concentrations occur about 3 hours after oral administration) and the terminal elimination half-life is about 10 hours.

Indications:

Monocast is indicated for prophylaxis and management of chronic asthma.

Dosage & Administration:

- Adults and children 12 years of age and older:

20 mg (one tablet) twice daily, on an empty stomach, at least 1 hour before or 2 hours after meals.



- Patients with Renal Impairment:

Dosage adjustment is not required for patients with renal impairment.

Packing:

Containers of 20 tablets (2 strips x 10 tablets).